In vivo studies using a DSS-induced colitis mouse model further demonstrated that HME-MUL-F2 could alleviate colitis symptoms, increase body weight and colon length, reduce pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, MCP-1), and increase anti-inflammatory cytokines (IL-10). This evidence concerns the gene IL6 and colitis.